ALK阳性肺腺癌脑转移个例诊治分析  

The diagnosis and treatment of ALK-positive lung adenocarcinoma with brain metastasis: case report

作　　者：何冬云 王凤楠 邓秋华[2] 黄丽燕[2] 杨海虹[1] Dong-yun;WANG Feng-nan;DENG Qiu-hua;HUANG Li-yah;YANG Hai-hong(Thoracic tumor department,Guangzhou institute of respiratory disease,the First Affiliated Hospital of Guaagzhou Medical University,Guangzhou 510120,Guangdong,China)

机构地区：[1]广州医科大学附属第一医院广州呼吸健康研究院胸部肿瘤科,广东广州510120 [2]广州医科大学附属第一医院广州呼吸健康研究院转化医学中心,广东广州510120

出　　处：《广东医学》2019年第1期55-59,共5页Guangdong Medical Journal

摘　　要：目的探讨KIT/PDGFRA基因扩增导致1例ALK阳性肺腺癌脑转移的临床表现和治疗方法。方法报道KIT/PDGFRA基因扩增导致1例ALK阳性肺腺癌脑转移的临床诊断与治疗。结果患者脑转移瘤手术组织采用第2代基因测序(NGS)方法检测,结果示KIT和PDGFRA基因扩增。治疗上克唑替尼联合KIT/PDGFRA酪氨酸激酶抑制剂(TKI),获得良好疗效。结论 ALK阳性肺腺癌患者脑转移发生机制尚未明确,可以选择克唑替尼联合颅脑放疗或第2代ALK-TKI治疗。如患者治疗时单独出现颅内进展,可行组织活检,明确分子病理状态,指导治疗。Objective To investigate the clinical manifestations and treatment of a case of brain metastases in ALK-positive lung adenocarcinoma caused by KIT/PDGFRA gene amplification.Methods A case of KIT/PDGFRA gene amplification resulted in a brain metastasis of ALK-positive lung adenocarcinoma were reported with literature review.Results The surgical tissue of patients with brain metastases was detected by second-generation gene sequencing( NGS).The results showed that KIT and PDGFRA genes were amplified.Treatment with crizotinib in combination with KIT/PDGFRA tyrosine kinase inhibitor( TKI) has achieved good results.Conclusion The mechanism of brain metastasis in patients with ALK-positive lung adenocarcinoma is unclear.Crizotinib combined with brain radiotherapy or second-generation ALK-TKI therapy may be selected.Biopsy is feasible as intracranial progression.

关 键 词：KIT/PDGFRA基因扩增 ALK阳性 脑转移瘤 肺腺癌 

分 类 号：R739.41[医药卫生—肿瘤]